Optimization of Systemic Treatment Strategies in Elderly Patients With Advanced Solid Malignancies

Inclusion Criteria: * Age ≥ 70 years * Diagnosis of advanced cancer of colorectum, breast or prostate * Standard first line palliative treatment with cytotoxic agents will be started (Folfox, Xelox, capecitabine, paclitaxel or docetaxel) * Estimated life expectancy ≥ 3 months * Able to give informed consent * WHO performance status ≤ 2 * Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the treatment and follow-up schedule; those conditions should be assessed with the patient before registration in the trial * No other severe medical or psychiatric conditions that in the judgment of the investigator renders the patient inappropriate for inclusion in this study. * Before patient registration, written informed consent must be given and documented to ICH/EUCGCP, national/local regulatory requirements and the local rules followed in our institution Exclusion Criteria: * Presence of cytopenia due to iron-, vitamin B12 and folic acid deficiency or hemolysis, unless adequately supplemented. * Creatinine clearance ≤ 30 ml/min * Serum AST and ALT ≥ 2.5 x ULN, in case of liver metastases serum AST and ALT ≥ 5 x ULN * In case of therapy with Docetaxel/Paclitaxel serum bilirubin ≥ 1.5 x ULN